Business Wire

Vista Group Signs Aeon Entertainment, Japan’s Largest Cinema Chain

Jaa

Vista Group International (NZX & ASX: VGL), the world’s leading provider of software solutions for the global film industry, has signed Aeon Entertainment Co Ltd (‘Aeon’), its first customer in Japan. Japan is one of the “top 5” film exhibition markets in the world by Box Office revenue.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180510006431/en/

Vista Group companies Vista Entertainment Solutions (‘Vista Cinema’) and Movio, will provide their respective cinema management and marketing data analytics software solutions to Aeon who operate 91 cinema sites throughout Japan comprising 774 screens.

The Agreement represents the realisation of a long-time goal for Vista Cinema, which has grown its global market share in the large circuit market to 38% over 20 years – but without the inclusion of Japan. The successful negotiation of the Agreement conducted over more than two years was achieved with the support of Vista’s in-market Business Partner VINX Corporation (‘VINX’), who will continue to work with Vista to execute the new Agreement including the deployment of Vista’s software and on-going support.

VINX has established a new cinema division with a focus on selling and supporting Japanese exhibitors. “Our partnership with Vista has initiated this new division within VINX and we’re very excited about the opportunity it represents. It is difficult to promote the foreign software package in Japan since we have developed customised systems for every customer. This partnership will allow us not only to expand our business together in Japan, but also it will help us enhance our global strategy. I am convinced that this Agreement will be the very first step of a great development and success for the Japanese cinema industry,” says Toshiya Fujita, President of VINX.

“With perseverance, determination and hard work and with the support of our partner VINX Corporation, we’ve finally realized our long-term goal of establishing the Vista brand in Japan,” said Kimbal Riley, Chief Executive of Vista Group. “With the implementation of Vista Cinema’s industry-leading cinema management software system and Movio’s unsurpassed marketing data insights and solutions, Aeon will absolutely enhance its leadership position. We are humble and grateful to partner with an organization with the reputation and standing that Aeon holds in Japan and our experience of Aeon is that they are a devoted and extraordinary team of cinema professionals.”

The combination of Vista Loyalty and Movio is the high-end solution choice for Aeon; the integration of the two products enhances the capture of data and marketing analytics and audience insights to enable the execution of optimally-targeted and integrated marketing campaigns. Aeon’s Loyalty program and Box Office return is expected to accelerate using Vista Loyalty and Movio together.

The roll-out of the Vista Cinema and Movio solutions for Aeon will be completed by February 2020.

About VINX Corporation

VINX Corp has been assisting the retailing IT revolution in Japan and leading the standardization of retail systems as an expert in IT. VINX keeps creating innovative products and services by taking advantage of the know-how and long experience gained since 1991 in the retail industry while also providing high quality IT services to domestic and foreign countries, bringing together the power of the Fujisoft Group. With more than 1,250 employees, VINX has developed ‘Cross-border IT Solutions’ to solve overseas issues related to the IT of retailing companies, boasting Japanese quality and providing network construction among Japanese, Chinese and other Asian countries. To fully support the ‘China and ASEAN Strategy’ of the Japanese retailing industry, VINX has established affiliates in China, Malaysia, and Vietnam, and has expanded businesses in Asia to carry out offshore development in the field, and equipment procurement in local areas.
Website: www.vinx.co.jp

About Vista Group International

Vista Group International (Vista Group) is a public company, listed on both the New Zealand and Australian stock exchanges (NZX & ASX: VGL). The Group provides software and additional technology solutions across the global film industry. Cinema management software is provided by Vista Cinema, the core business of the Group. Movio (authority in moviegoer data analytics), Veezi (cloud-based SaaS software for the Independent Cinema Market), movieXchange (connecting the movie industry to simplify the promotion and sale of movie tickets), Maccs (film distribution software), Numero (box office reporting software for film distributors and cinemas), Cinema Intelligence (business intelligence solutions), Powster (creative studio and marketing platform for movie studios) and Flicks (moviegoer ‘go to’ portal for movie information) provide an innovative range of complementary products across additional film industry sectors, from production and distribution, to cinema exhibition through to the moviegoer experience. Vista Group has offices located in New Zealand (Auckland HQ), Sydney, Los Angeles, London, Shanghai, Beijing, Mexico City, South Africa, the Netherlands and Romania.
Website: www.vistagroup.co
LinkedIn: www.linkedin.com/company/vista-group-limited

About Vista Entertainment Solutions

Vista Entertainment Solutions Ltd (‘Vista Cinema’) is the world leader in cinema management software solutions with installations in more than 90 countries around the world and an estimated 38% global market share in the Large Cinema Circuit market. The Vista Cinema software product line comprises multiple modules, integrated and scalable, suited to cinema exhibitors operating 20+ screens and 100s of cinemas. Vista Cinema is head-quartered in Auckland, New Zealand.
Website: www.vista.co
Twitter: @VistaCinema
LinkedIn: www.linkedin.com/company/vista-entertainment-solutions

About Movio

Movio, a company of Vista Group International (NZX & AXS: VGL), is the global leader in marketing data analytics and campaign management solutions, revolutionizing the way the film industry interacts with moviegoers. With a global database of over 100 million moviegoers, 750 million behavioral and transactional records and more than 5000 movie titles, Movio is the world’s most comprehensive source of moviegoer data. The company’s investment in data science and machine learning has produced market-leading technologies that redefine the possibilities of movie marketing. Movio empowers marketers to connect moviegoers with their ideal movie via online and offline channels, and link campaign data with actual ticket purchases to close the loop and measure campaign effectiveness.
Website: www.movio.co
Twitter: @MovioHQ
LinkedIn: www.linkedin.com/company/movio

Contact information

For Vista Group International/USA
Maggie Begley/MBC
+1 310 390 0101
maggie@mbcprinc.com
or
For Vista Group International/NZ
Christine Fenby, +64 21 727 006
christine.fenby@vista.co
or
For VINX Corporation/Japan
Hitoshi Chiyoda, +81 3 5209 7359
h.chiyoda@vinx.co.jp

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 15:00Tiedote

Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior

NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 15:00Tiedote

NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip

Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 14:27Tiedote

At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea

Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 14:00Tiedote

Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba

ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 13:11Tiedote

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 13:06Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme